Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2013-10-07 Capital/Financing Update
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Cleansing notice and ASX Appendix 3B 13 pages 194.6KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement dated 8 October 2013, titled 'Cleansing notice under section 708A the Corporations Act 2001 (Cth)'. It details the completion of a share issue under an underwritten share purchase plan, including the number of shares issued, issue price, and purpose of the issue. The document includes an Appendix 3B, which is a standard form for new issue announcements and applications for quotation of additional securities on the ASX. The content focuses on capital raising activities, share issuance, and compliance with relevant securities laws. There is no financial performance data, earnings information, or management discussion. The document is not a report but an announcement related to capital structure changes and fundraising. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2013-10-07 English
Results of share purchase plan 2 pages 110.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 3 October 2013 regarding the closing of a Share Purchase Plan (SPP) by Genetic Technologies Limited. It details the amount raised, the issue price of shares, underwriting arrangements, and future shareholder approval for additional share issuance. The content focuses on capital raising activities and share subscription details. There are no financial statements, earnings data, or management discussion of results. The document is not a full financial report but an update on financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 5141 characters, sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2013-10-02 English
GTG announces further record number of BREVAGen tests 2 pages 113.5KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated October 1, 2013, reporting on the number of BREVAGen test samples received during the quarter ended September 30, 2013. It highlights growth figures and market adoption trends but does not contain detailed financial statements or comprehensive financial analysis. The document is relatively short (4145 characters) and reads like a quarterly operational update rather than a full interim or annual report. It does not present full financial results or management discussion and analysis. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about business activity and growth, not a full financial report or earnings release.
2013-09-30 English
Termination of patent re-examination 2 pages 110.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 30 September 2013 regarding the issuance of a Patent Re-Examination Certificate by the USPTO confirming the reaffirmation of patent claims. It discusses patent legal status and related licensing implications. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about intellectual property status, not a financial report or meeting material. It is short (4296 characters) and serves as a formal announcement to the market. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2013-09-29 English
Financial Report - 30 June 2013 74 pages 492.5KB
Annual Report Classification · 100% confidence The document is titled 'Financial Report for the year ended 30 JUNE 2013' and contains detailed sections such as Corporate Information, Directors' Report, Operating and Financial Review, and Auditor's Report. It includes comprehensive information about the company's activities, financial results, corporate structure, and governance for the full fiscal year ending June 30, 2013. The length of the document is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The presence of an Auditor's Report and detailed financial and operational review confirms this is a full annual report. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2013
2013-09-26 English
ImmunAid fundraising update 1 page 102.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 26 September 2013 regarding ImmunAid Limited commencing a second round fundraising program. It discusses the issuance of ordinary shares to investors and the use of proceeds for expanding patent portfolios and trials. There are no financial statements, detailed financial data, or comprehensive report content. The document is a corporate announcement about fundraising activity, not a full financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it provides an update on company fundraising activities.
2013-09-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.